Why is Altimmune, Inc. (ALT) stock trending?
- Goldman Sachs increased its position in Altimmune, Inc. (ALT) by 12% last quarter.
- Several notable investors, including Two Sigma, Trails Edge Capital, Point72, Fidelity, and Citadel, increased their positions in ALT through 13F filings.
- The CEO's actions to protect shareholder value are unclear, with one post questioning the CEO's efforts to do so.
| Attention | 30-day average attention | Change | |
|---|---|---|---|
| ALT | |||
| ALT | 0.25% | 0.076% | +0.17 pts |
Is ALT stock sentiment bullish or bearish?
| Bullish | Bearish | ||
|---|---|---|---|
| ALT | |||
| ALT | 43% | 57% | |
| ALT, 30-day average | |||
| ALT, 30-day average | 62% | 38% | |
| Healthcare sector | |||
| Healthcare sector | 61% | 39% | |
| All stocks | |||
What are investors saying about ALT stock?
We train models to sort every post about Altimmune, Inc. into topics, then summarize what each group is saying. Each bar is the share of the engagement on ALT posts that went to that topic.
| Share of engagement | 30-day average share | ||
|---|---|---|---|
| Technical Analysis chart patterns and price levels | |||
| Technical Analysis chart patterns and price levels | 4% | 4% | |
What does technical analysis say about ALT stock?
- The $ALT stock price is currently weak, with the author expecting it to drop below $1 or $0.50 after the next Triple Witching Day, and believes a reverse split is likely.
- The author believes the stock is oversold and expects a violent green candle, but notes that the price may drop further if there is no uptick in buying pressure.
What is the latest news on ALT stock?
- Altimmune, Inc. (ALT) Presents at American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2026 - Slideshow
2026-11-14. The following slide deck was published by Altimmune, Inc.
Seeking Alpha · 4d ago - Altimmune director Wayne Pisano buys $16,350 in company stockInvesting.com · 4d ago
- ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding ConcernsYahoo Finance · 5d ago
- Citizens reiterates Altimmune stock rating on expanding pemvidutide dataInvesting.com · 5d ago
- Altimmune: Still Too Late And Too Capital-Intensive
Altimmune remains a Sell as pemvidutide lacks clear differentiation in the competitive MASH landscape. Read more on ALT stock here.
Seeking Alpha · 6d ago
Who is talking about ALT stock?
| Newcomers | Regulars | ||
|---|---|---|---|
| ALT | |||
| ALT | 8% | 92% | |
| ALT, 30-day average | |||
| ALT, 30-day average | 6% | 94% | |
| All stocks | |||
| All stocks | 43% | 57% | |
How does ALT compare with other Healthcare stocks?
We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each bar is that share.
| Share of Healthcare attention | ||
|---|---|---|
| ALT | ||
| ALT | 2.5% | |
| SLS | ||
| SLS | 33% | |
| CAPR | ||
| CAPR | 8% | |